PMID- 12381954
OWN - NLM
STAT- MEDLINE
DCOM- 20030303
LR  - 20171101
IS  - 0250-8095 (Print)
IS  - 0250-8095 (Linking)
VI  - 22
IP  - 5-6
DP  - 2002 Sep-Dec
TI  - Clinical profiles and outcomes of end-stage renal failure patients with late 
      initiation of renal replacement therapy based on uremic symptoms under intensive 
      renoprotective therapies.
PG  - 521-31
AB  - AIM: This study describes the clinical profiles and outcomes of renal failure 
      patients with late initiation of renal replacement therapies (RRT) based on 
      uremic symptoms under intensive treatment prior to the start of RRT (IT). 
      METHODS: Thirteen patients (male 10, female 3) with end-stage renal disease who 
      preferred to wait for the initiation of RRT until uremic symptoms appeared 
      regardless of serum creatinine (s-Cr) and 24-hour creatinine clearance (24-hour 
      Ccr) were chosen. All patients received IT including a low-protein diet, 
      antihypertensive drugs including enalapril, erythropoietin and others to prevent 
      and manage uremic states until the initiation of RRT. Clinical findings at the 
      initiation of RRT and the outcomes after the start of RRT were examined. RESULTS: 
      RRT was initiated 23.6 +/- 16.9 months after IT without any complication in all 
      patients when mild uremic symptoms appeared. Uremic symptoms, blood pressure, 
      serum albumin, potassium, calcium and urinary Cr excretion were well controlled 
      except inorganic phosphate, hemoglobin and cardiac size. 24-hour Ccr and s-Cr 
      were 3.4 +/- 0.7 ml/min and 17.4 +/- 3.8 mg/dl at initiation of RRT. The outcomes 
      of all the patients were all well during chronic RRT. CONCLUSION: Intensive 
      treatment prior to the start of RRT can diminish uremic symptoms and 
      complications so that RRT might be initiated safely and with fewer problems, even 
      in the face of lower 24-hour Ccr and markedly higher s-Cr.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Kaizu, Kazo
AU  - Kaizu K
AD  - Kidney Center, University of Occupational and Environmental Health (UOEH), 
      Nakama, Japan. k-kaizu@clnc.uoeh-u.ac.jp
FAU - Uriu, Kohei
AU  - Uriu K
FAU - Inada, Yoshifumi
AU  - Inada Y
FAU - Hashimoto, Osamu
AU  - Hashimoto O
FAU - Mizobe, Takamitsu
AU  - Mizobe T
FAU - Takagi, Iichiro
AU  - Takagi I
FAU - Ito, Aki
AU  - Ito A
FAU - Suzuka, Kanako
AU  - Suzuka K
FAU - Qie, Yue Ling
AU  - Qie YL
FAU - Lee, Wei
AU  - Lee W
FAU - Miyamoto, Hidemitsu
AU  - Miyamoto H
FAU - Tanaka, Yoshiya
AU  - Tanaka Y
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Serum Albumin)
RN  - AYI8EX34EU (Creatinine)
RN  - RWP5GA015D (Potassium)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Antihypertensive Agents
MH  - Blood Pressure/physiology
MH  - Calcium/blood
MH  - Creatinine/blood/urine
MH  - Diet, Protein-Restricted
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/*complications/*therapy
MH  - Male
MH  - Potassium/blood
MH  - *Renal Replacement Therapy
MH  - Serum Albumin/analysis
MH  - Time Factors
MH  - Treatment Outcome
MH  - Uremia/*etiology
EDAT- 2002/10/17 04:00
MHDA- 2003/03/04 04:00
CRDT- 2002/10/17 04:00
PHST- 2002/10/17 04:00 [pubmed]
PHST- 2003/03/04 04:00 [medline]
PHST- 2002/10/17 04:00 [entrez]
AID - 65290 [pii]
AID - 10.1159/000065290 [doi]
PST - ppublish
SO  - Am J Nephrol. 2002 Sep-Dec;22(5-6):521-31. doi: 10.1159/000065290.